In:
Current Drug Delivery, Bentham Science Publishers Ltd., Vol. 19, No. 5 ( 2022-09), p. 560-586
Abstract:
The conventional anticancer chemotherapies not only cause serious toxic effects but also
produce resistance in tumor cells exposed to long-term therapy. Usually, the selective killing of metastasized cancer cells requires long-term therapy with higher drug doses because the cancer cells develop
resistance due to the induction of poly-glycoproteins (P-gps) that act as a transmembrane efflux pump to transport drugs out of the cells. During the last few decades, scientists have been exploring new anticancer
drug delivery systems such as microencapsulation, hydrogels, and nanotubes to improve bioavailability, reduce drug-dose requirement, decrease multiple drug resistance, and save normal cells as
non-specific targets. Hopefully, the development of novel drug delivery vehicles (nanotubes, liposomes, supramolecules, hydrogels, and micelles) will assist in delivering drug molecules at the specific target
site and reduce undesirable side effects of anticancer therapies in humans. Nanoparticles and lipid formulations are also designed to deliver a small drug payload at the desired tumor cell sites for their anticancer
actions. This review will focus on the recent advances in drug delivery systems and their application in treating different cancer types in humans.
Type of Medium:
Online Resource
ISSN:
1567-2018
DOI:
10.2174/1567201818666211214112710
Language:
English
Publisher:
Bentham Science Publishers Ltd.
Publication Date:
2022
SSG:
15,3
Bookmarklink